At an institutional investors' conference on December 11, TSH Biopharm (東生華) General Manager Yang Ssu-yuan announced a new five-year plan (2026–2030) focused on four core growth engines to double revenue and increase its drug license portfolio from 10 to 20 licenses.

Strategic Engines:

1. Niche Product Development: Focusing on Ophthalmology and CNS Rare Diseases to optimize product structures.
2. Taiwan Channel Optimization: Increasing the ratio of self-pay products and cost efficiency.
3. Overseas Expansion: Leveraging existing licenses in Malaysia and Macau to generate substantial revenue.
4. Inorganic Growth: Evaluating strategic M&A and expanding subsidiaries.

Product Pipeline:

• Varenate (Smoking Cessation) and a First-in-Class dry eye nasal spray are expected to launch in January 2026.
• Presbyopia (Old-age Nearsightedness): The U.S. FDA action date for the licensed presbyopia drug is January 28, 2026. If approved, TSH Biopharm plans to file for Taiwan registration in Q1 2026, aiming for 2027 approval to become the first domestic prescription drug for presbyopia.

Resource: 東生華四大引擎 挑戰年營收翻倍